OpenAI‘s recent announcement of its generative AI video tool, Sora, has sent ripples through Hollywood, prompting notable figures like Tyler Perry to halt an $800 million studio expansion after witnessing Sora‘s capabilities. The tool transforms text prompts into dynamic video scenes featuring camera motion, complex subject movements, and environmental effects. However, concerns have been raised about the potential impact of such generative video tools on the proliferation of deepfake videos.
In the realm of AI chipmaking, Nvidia experienced a remarkable 16% surge in its stock price, equivalent to a staggering $273 billion increase in market capitalization, following the release of its quarterly earnings. The report highlighted a tripling of company revenue and a ninefold rise in profits year-over-year. Jensen Huang, Nvidia’s Founder and CEO, foresees significant future developments, stating, “We are one year into generative A.I. … My guess is we are literally into the first year of a 10-year cycle of spreading this technology into every single industry.”
Meanwhile, a judge in the Northern District of California dismissed parts of an AI copyright lawsuit targeting OpenAI and its generative AI ChatGPT. The lawsuit alleged copyright infringement by OpenAI, including claims from comedian Sarah Silverman and other prominent authors. The court deemed the plaintiffs’ assertion that “every output of the OpenAI Language Models is an infringing derivative work” insufficient for establishing vicarious copyright infringement. Additionally, claims under the Digital Millennium Copyright Act were dismissed due to the failure to allege ChatGPT’s reproduction of copyrighted works without proper copyright management information. The direct copyright infringement claims remain pending, and the court granted the plaintiffs the opportunity to file an amended complaint.
In the field of biology, former Google DeepMind AI researchers have founded Bioptimus, a French startup with the ambitious goal of creating a universal AI model for biology. While various AI models exist for specific biological aspects, Bioptimus aims to provide a holistic view. Challenges are expected, particularly regarding access to high-quality data, especially given the stringent privacy laws of the European Union.